Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00683137 |
The study was done to evaluate the pain relief and safety of 2 valdecoxib doses compared to placebo in patients with moderate or severe pain following bunionectomy surgery, and to evaluate the effect of the 2 valdecoxib doses compared to placebo on health outcome measures and on the occurrence of opioid related symptoms.
Condition | Intervention | Phase |
---|---|---|
Pain Hallux Valgus |
Drug: valdecoxib Drug: valdecoxib/placebo |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study |
Official Title: | Clinical Protocol for a Multiple Dose Randomized, Double-Blind, Placebo Controlled Study of the Analgesic Efficacy and Safety of Valdecoxib Compared to Placebo in Patients for Treatment of Post-Surgical Pain From Bunionectomy Surgery |
Enrollment: | 450 |
Study Start Date: | October 2002 |
Study Completion Date: | February 2003 |
Arms | Assigned Interventions |
---|---|
Arm 1: Active Comparator |
Drug: valdecoxib
valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then a valdecoxib 20 mg tablet by mouth once daily on Days 2 through 5
|
Arm 2: Active Comparator |
Drug: valdecoxib
valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then a valdecoxib 20 mg tablet by mouth twice daily on Days 2 through 5
|
Arm 3: Active Comparator |
Drug: valdecoxib/placebo
valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then placebo on Days 2 through 5
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Responsible Party: | Pfizer, Inc. ( Director, Clinical Trial Disclosure Group ) |
Study ID Numbers: | VALA-0513-144, A3471084 |
Study First Received: | March 31, 2008 |
Last Updated: | May 22, 2008 |
ClinicalTrials.gov Identifier: | NCT00683137 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Hallux Valgus Anti-Inflammatory Agents Cyclooxygenase Inhibitors Pain Musculoskeletal Diseases Analgesics, Non-Narcotic Anti-Inflammatory Agents, Non-Steroidal |
Analgesics Peripheral Nervous System Agents Congenital Abnormalities Valdecoxib Antirheumatic Agents Foot Deformities |
Anti-Inflammatory Agents Hallux Valgus Molecular Mechanisms of Pharmacological Action Cyclooxygenase Inhibitors Physiological Effects of Drugs Enzyme Inhibitors Pharmacologic Actions Musculoskeletal Diseases Sensory System Agents |
Analgesics, Non-Narcotic Therapeutic Uses Anti-Inflammatory Agents, Non-Steroidal Analgesics Peripheral Nervous System Agents Antirheumatic Agents Valdecoxib Foot Deformities Central Nervous System Agents |